Vaccitech Renames as Barinthus Biotherapeutics to Highlight
New Corporate Brand to be Unveiled at AASLD Liver Meeting® 2023 with Interim Data OXFORD, United Kingdom, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Barinthus...
Source: globenewswire.com
📰 Repeat Dosing News
Repeat Dosing News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Repeat Dosing. Real-time updates on events, politics, business and more.
Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023
Imdusiran data will be highlighted in late breaking presentation WARMINSTER, Pa., Oct. 11, 2023 -- Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its...
Source: marketscreener.com
Hansa Biopharma announces encouraging high-level results for first-in-human trial of HNSA-5487
LUND, Sweden, Oct. 9, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in...
Stephanie Kenney Hansa Biopharma Prnewswire Hansa Biopharma Klaus Sindahl Nasdaq Stockholm Novel Immunoglobulin Cleaving Enzymes
Source: europapress.es
Hansa Biopharma announces encouraging high-level results for first-in-human trial of HNSA-5487
HNSA-5487 is a next-generation IgG-cleaving enzyme and the lead candidate in the NiceR development program Lund, Sweden, October 9, 2023. Hansa Biopharma, Hansa , a pioneer in enzyme technology for...
Hansa Biopharma Stephanie Kenney Klaus Sindahl Vp Global Corporate Affairs Nasdaq Stockholm Novel Immunoglobulin Cleaving Enzymes
Source: marketscreener.com
Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients
– PRGN-3005 was well-tolerated with no dose limiting toxicities, no CRS greater than Grade 2, and no neurotoxicity – – PRGN-3005 cells demonstrated expansion...
Source: prnewswire.com
Poseida Therapeutics Announces Multiple Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting
/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with...
United States Los Angeles American Society Of Gene Prnewswire Poseida Therapeutics Inc Technology Reactivates Fetal Hemoglobin Poseida Therapeutics Inc
Source: prnewswire.com
BioXcel Therapeutics : Other Information - Form 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT ... | April 20, 2023
United States Richard Steinhart K While The Company Commission File Number Bioxcel Therapeutics Inc Securities Exchange
Source: marketscreener.com